SkyePharma agrees Flutiform exclusive licence deal with Kyorin in Japan
On April 22, 2008, SkyePharma PLC signed an exclusive Development, Distribution and License Agreement for Flutiform, its lead development product for the treatment of asthma, with Kyorin Pharmaceutical Co., Ltd., a subsidiary of Kyorin Co., Ltd. for Japan.
SkyePharma was advised by Stuart Richards and Paul Ranson of Fasken Martineau Stringer Saul.